The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

开始日期2024-10-10

申办/合作机构

Eli Lilly & Co.

NCT06169982

/ Completed临床1期

A Phase 1, Open-Label, Multiple-Dose Study to Investigate Steady-State Pharmacokinetics and Pharmacodynamics During a Euglycemic Clamp of LY3209590 in Participants With Type 2 Diabetes Mellitus

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

开始日期2023-12-07

申办/合作机构

Eli Lilly & Co.

NCT05914688

/ Completed临床1期

A Bioequivalence Study of Subcutaneous Injections of LY3209590 in Two Formulations in Healthy Participants

The main purpose of this study is to compare the two formulations of LY3209590 in healthy participants. Study participants will be administered each formulation at separate study visits. Blood samples will be taken to compare how the body handles study drugs. The information about any adverse effects experienced will be collected and the tolerability of LY3209590 will also be evaluated.
Screening is required within 28 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 184 days including screening.

开始日期2023-06-26

申办/合作机构

Eli Lilly & Co.

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的临床结果

登录后查看更多信息

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的转化医学

登录后查看更多信息

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的专利（医药）

登录后查看更多信息

120

项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的文献（医药）

2025-10-01·JOURNAL OF DIABETES AND ITS COMPLICATIONS

Degludec insulin versus efsitora insulin in diabetes mellitus management: A systematic review and meta-analysis

Review

作者: Gallo Ruelas, Mariano ; Flávio-Reis, Victor Hugo Palhares ; Queiroz, Ivo ; Barbosa, Lucas Mendes ; de Oliveira, Helen Michaela ; Zamora, Fernanda Valeriano ; Cavalcante, Deivyd Vieira Silva

PURPOSE:

To compare the efficacy and safety of next-generation basal insulin efsitora versus insulin degludec in managing type 1 and type 2 diabetes.

METHODS:

We systematically searched PubMed, Embase, and CENTRAL databases until October 2024. This study followed PRISMA guidelines. Statistical analyses were performed using R version 4.4.1. The risk of bias was assessed using the RoB2 tool, and the quality of evidence was evaluated using the GRADE approach. This study was registered in PROSPERO under protocol CRD42024597806.

RESULTS:

Six randomized controlled trials involving 2590 patients were included in the analysis. Of these, 1376 (53.13 %) received efsitora insulin. No significant differences were observed between efsitora and degludec in glycemic efficacy outcomes, including HbA1c reduction, fasting blood glucose, weight change, and proportion of patients achieving HbA1c <7 %. Regarding safety outcomes, most endpoints, such as adverse events, injection site reactions, hypersensitivity, severe hypoglycemia, and mortality, were comparable between groups, with no significant subgroup effects. However, subgroup analysis revealed a lower incidence of nocturnal hypoglycemia with efsitora in patients with type 2 diabetes, and a higher rate of serious adverse events in patients with type 1 diabetes, suggesting potential population-specific differences in safety profiles.

CONCLUSION:

Efsitora and degludec insulins show similar overall efficacy and safety in the management of diabetes. However, subgroup analyses indicate that patient-specific factors, such as diabetes type, may influence the risk of certain adverse events. These findings support the importance of individualized insulin selection based on patient characteristics and risk profiles.

2025-09-01·Diabetes Technology & Therapeutics

Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study

Article

作者: Frías, Juan ; Gleissner, Stephanie ; Kazda, Christof ; Dassau, Eyal ; Mitra, Jit ; Brazg, Ronald ; Katz, Michelle ; Xue, Jie

Introduction: For people with type 2 diabetes (T2D), optimal glycemic control is critical. Digital health interventions are a practical approach to improve T2D self-management. This study explored the safety and functionality of a novel clinical decision-support (CDS) application for individualized dosing of insulin efsitora (efsitora), a once-weekly basal insulin receptor agonist. Participants and Methods: This was a 16-week, multicenter, open-label early feasibility study in adults with T2D with or without basal insulin. Investigators requested an efsitora dose from the CDS algorithm and either overrode or accepted the recommendation. Dose recommendation overrides (primary endpoint), finger-stick glucose, blinded continuous glucose monitoring metrics, and hypoglycemic events were evaluated. Results: Two sequential cohorts consisted of 68 participants; each cohort included insulin-naïve and basal-switch participants. In both cohorts, mean glycated hemoglobin (HbA1c) for basal-switch participants ranged from 7.9% to 8.5%. Mean HbA1c for insulin-naïve participants ranged from 8.1% to 8.3%. CDS dosing recommendation overrides occurred for 0.7% of injections for basal-switch participants and for 1.0% of injections for insulin-naïve participants in Cohort 1. For Cohort 2, overrides occurred for 1.3% of injections for insulin-naïve participants, with no overrides for basal-switch participants. HbA1c was significantly reduced (P < 0.05) from baseline to Week 16 in both subgroups for both cohorts. The proportion of participants with fasting blood glucose within the targets increased from baseline to Week 16 in both subgroups for both cohorts. No level 3 hypoglycemia was observed. Conclusions: The novel CDS algorithm showed promising clinical performance and favorable investigator confidence as determined by a low rate of dose overrides.

2025-08-01·EUROPEAN JOURNAL OF NEUROSCIENCE

Efficacies of Bifidobacterium and Fecal Microbiota Transplantation in Rats With Chronic Hepatic Encephalopathy Assessed by [¹⁸F]PBR146 Imaging of Neuroinflammation

Article

作者: Yang, Gui Fen ; Jiang, Jing Zhou ; Wu, Shi Yao ; Zhang, Jun ; Zhang, Long Jiang ; Luo, Song ; Lu, Guang Ming ; Kong, Xiang

ABSTRACT:

Neuroinflammation significantly contributes to hepatic encephalopathy (HE). The radiotracer [18F]PBR146 is used for in vivo imaging of neuroinflammation. Promising treatments like Bifidobacterium (BIF) and fecal microbiota transplantation (FMT) are being explored for HE. This study evaluated and compared the efficacies of BIF and FMT in reducing neuroinflammation in chronic HE rats induced by bile duct ligation (BDL) using [18F]PBR146 micro‐PET/CT imaging. Thirty rats were divided into four groups: (1) Sham‐operated rats received normal saline (Sham + NS group), (2) BDL rats treated with NS (BDL + NS group), (3) BDL rats administered with BIF (BDL + BIF group), and (4) BDL rats administered with FMT (BDL + FMT group). Following the establishment of the chronic HE model, we conducted sequential behavioral assessments, collected fecal samples, and performed micro‐PET/CT scans. Data analysis included average %ID/g values across the whole brain and specific regions, alongside biochemical and pathological evaluations. No significant differences in behavioral results or levels of IL‐1β, IL‐6, IL‐10, and TNF‐α were found among the groups. While there was no significant difference in global brain uptake values of [18F]PBR146 among the four groups (p = 0.053), regional analyses showed significant discrepancies in areas such as the bilateral accumbens and retrosplenial cortex. The Sham + NS group was enriched with Parasutterella, Streptococcus, and Anaeroplasma, the BDL + FMT group had Enterococcus, Aestuariispira, Lactobacillus, Pseudomonas, and Globicatella, while the BDL + BIF group contained Enterorhabdus. Results indicated that BIF inhibited neuroinflammation in BDL rats, whereas FMT showed no positive effects, possibly due to dysbiosis. Notably, [18F]PBR146 could effectively and noninvasively monitor the efficacies of gut‐targeted treatments in chronic HE models.

项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的新闻（医药）

2025-06-24

·医学新视点

一年少打约300针！NEJM、Lancet三连发：每周一次，长效胰岛素有效降糖

约三分之一的2型糖尿病患者在确诊后8年内需要胰岛素治疗。对低血糖的担忧和高频注射胰岛素带来的不便会让患者难以坚持按最佳剂量使用胰岛素。近年来，长效胰岛素的出现正在改变这样的挑战。Efsitora是一种每周一次皮下注射的基础胰岛素，它是一种融合蛋白，结合了新型单链胰岛素变体与人IgG2 Fc结构域。Efsitora与人胰岛素受体的结合亲和力比内源性胰岛素弱约两个数量级，这意味着这可以延长胰岛素活性，作用时间更长；同时，由于其具有较低的峰谷比，有望在整一周内帮助患者保持更稳定的血糖水平。QWINT系列研究评估了efsitora的安全性和有效性。此前发表的QWINT-2试验显示，在未接受过胰岛素治疗的2型糖尿病成人中，每周一次的efsitora治疗52周降低糖化血红蛋白（HbA1c）的效果不劣于每日一次的常用基础胰岛素；QWINT-5试验在1型糖尿病成人患者中证实了这一点。在第85届美国糖尿病协会（ADA）学术会议上，QWINT-1、QWINT-3和QWINT-4的积极结果公布，并分别同步发表于《新英格兰医学杂志》（NEJM）和《柳叶刀》（The Lancet）。这三项试验分别针对首次使用胰岛素、既往使用每日基础胰岛素、既往使用每日基础胰岛素和餐时胰岛素的2型糖尿病成年患者。在每项试验中，每周一次的efsitora在降低HbA1c方面均不劣于常用的每日基础胰岛素，且总体安全性相似。这三项研究的结果强化了efsitora通过每周给药简化胰岛素管理的潜力，意味着患者有望每年可减少近300次的胰岛素注射。QWINT-1试验：针对首次使用胰岛素患者截图来源：The New England journal of medicineQWINT-1试验是一项为期52周的开放标签、达标治疗3期试验，共795名既往未接受过胰岛素的2型糖尿病成年患者接受随机分组，按1:1接受每周一次的efsitora或每日一次的甘精胰岛素U100治疗。Efsitora采用固定剂量方案，初始剂量为每次100单位，此后每4周按需调整剂量，递增至每次150、250和400单位，以达到空腹血糖80~130 mg/dL的治疗目标。甘精胰岛素的剂量根据标准算法每周或更频繁地调整，以达到相同的血糖目标值。按治疗方案评估（无论患者依从性如何，或是否引入其他挽救治疗），efsitora组患者的平均HbA1c水平从基线时8.20%降至第52周时的7.05%，降低1.19%；而对照组患者从8.28%降至7.08%，降低1.16%；组间降幅差异为-0.03%（95%CI 0.18%~0.12%），落在非劣效性界值（0.4%）内，证实了efsitora不劣于对照胰岛素。在第52周时，efsitora组更多患者达到HbA1c水平＜7.0%（57% vs 52%）。与对照组相比，efsitora导致的低血糖事件减少了43%（RR 0.57，95%CI 0.39~0.84）：在52周时，临床显著低血糖事件（<54 mg/dL）或严重（3级）低血糖事件的估计发生率在efsitora组和对照组分别0.50次/患者-年和0.88次/患者-年。Efsitora组患者的胰岛素用量更低，平均胰岛素总剂量为289.1单位/周，而对照组为332.8单位/周，efsitora组剂量调整需求更少，中位数为2次，而对照组为8次。QWINT-3试验：针对已使用基础胰岛素治疗患者截图来源：The LancetQWINT-3是一项为期78周的开放标签、达标治疗3期临床试验，共有986名目前接受基础胰岛素治疗（不含餐时胰岛素）、最多接受三种非胰岛素降糖药物且血糖控制不佳（HbA1c水平在6.5%-10.0%之间）的2型糖尿病成年患者参与随机分组，按2:1接受每周一次efsitora（n=655）或每日一次德谷胰岛素（n=331）。根据患者基线时的空腹血糖浓度选择不同的起始剂量，每周评估并按需调整胰岛素剂量，直至第12周，之后每月调整一次，以达到目标空腹血糖浓度为80-120 mg/dL。所有患者均至少接受过一剂研究治疗，871名（88%）完成了78周的治疗。按治疗方案估计，从基线到第26周，efsitora组的平均HbA1c水平从7.80%下降至6.99%，降低0.81%；对照组患者从7.79%下降至7.08%，降低0.72%；组间降幅差异为-0.09%（95%CI 0.19~0.01），符合非劣效性界值（0.4%），表明efsitora不劣于对照胰岛素。此外，从基线到第52周，efsitora组的HbA1c水平降幅显著更大（降低0.78% vs 降低0.59%；p=0.0014）。两组患者从基线到第78周的HbA1c水平变化相似。从连续血糖监测结果来看，在第52周前的4周监测期间，efsitora组血糖患者的24hr内血糖达标时间更高，但两组患者在26周和78周时的数据相似。安全性方面，从基线到第78周，两组患者的2级低血糖或3级（严重）低血糖事件发生率相似（RR 1.14，95%CI 0.83~1.56；p=0.43），efsitora组为0.84次/患者-年，对照组为0.74次/患者-年。Efsitora组16%患者、对照组11%患者发生了严重不良事件，其中分别有7例（1%）和1例（＜1%）与治疗有关。试验期间有9人死亡（efsitora组7人，degludec组2人），但均与研究治疗无关。QWINT-4试验：针对已使用基础胰岛素和餐时胰岛素的患者截图来源：The LancetQWINT-4是一项为期26周的开放标签、达标治疗3期试验，共730名既往使用基础胰岛素和餐时胰岛素以及最多三种非胰岛素降糖药物治疗、且HbA1c水平为7.0%-10.0%的2型糖尿病患者按1:1随机分组接受efsitora（n=365）或每日一次甘精胰岛素（n=365）治疗。治疗期间，所有参与者均接受餐时赖脯胰岛素治疗。根据患者基线时的空腹血糖浓度选择不同的起始剂量，每周评估并按需调整胰岛素剂量，直至第12周，之后每月调整一次，以达到目标空腹血糖浓度为80-120 mg/dL。按治疗方案估计，从基线到第26周，efsitora组患者的平均HbA1c水平从8.18%下降至7.17%，降低1.01%；对照组患者从8.18%下降至7.18%，降低1.00%；组间降幅差异为-0.01%（95%CI -0.14~0.12），符合非劣效性界值（0.4%），表明efsitora不劣于对照胰岛素。在第26周前的4周连续血糖监测期间，两组患者在24hr内血糖达到、高于、低于目标区间的时间比例均没有显著差异。第26周时，efsitora组的每周胰岛素总剂量（592.9单位/周 vs 666.4单位/周）、每周基础胰岛素剂量（391.6单位/周 vs 426.6单位/周）和平均每日餐时胰岛素剂量（27.0单位/日 vs 34.6单位/日）都明显更低。治疗期间，两组患者的总体2级或3级低血糖发生率相似（6.6次/患者-年 vs 5.9次/患者-年；ERR 1.11，95%CI 0.85~1.44；p=0.44）；两组不良事件发生率相似，efsitora组7%和对照组6%的患者报告了严重不良事件。图片来源：123RF根据公开信息，礼来公司计划在今年年底前向全球监管机构提交efsitora用于治疗成人2型糖尿病的上市申请，期待这款长效胰岛素早日为患者带来更便捷的血糖管理选择。推荐阅读每周一次，减重20.4%；血糖达标率超70%！NEJM连发两篇，双靶点疗法带来多重获益新药每周一次，93%中国患者成功减重，还降三高、尿酸和脂肪肝！纪立农教授领衔研究登《柳叶刀》子刊每周一次，不仅降糖，还能减重、减少使用胰岛素！《柳叶刀》子刊：新药为2型糖尿病治疗提供新选择每周一次，强效降糖！《柳叶刀》子刊：新药包含两大明星药成分，低血糖风险更低NEJM：每周一次，82%患者至少减重5%！中国患者有望在今年用上新药欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。封面图来源：123RF参考资料（可上下滑动查看）[1] Julio Rosenstock, et al., (2025). Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. The N Engl J Med, DOI: 10.1056/NEJMoa2502796[2] Julie R. Ingelfinger, Clifford J. Rosen. (2025). Weekly Insulins and Therapeutic Burden in Type 2 Diabetes. The N Engl J Med, DOI: 10.1056/NEJMe2508147[3] Athena Philis-Tsimikas, et al., (2025). Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet, DOI: 10.1016/S0140-6736(25)01044-X[4] Thomas Blevins, et al., (2025). Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet, DOI: 10.1016/S0140-6736(25)01069-4 External Link[5] Edith Wing-Kar Chowa, Elaine Chowa. (2025). Future of once-weekly insulins in type 2 diabetes: efficacy and safety. Lancet: DOI: 10.1016/S0140-6736(25)01098-0[6] Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials. Retrieved June 24, 2025 from https://investor.lilly.com/news-releases/news-release-details/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com分享，点赞，在看，传递医学新知

临床结果临床3期

2025-06-24

·求实药社

即将上市！礼来胰岛素周制剂3项III期研究结果公布

来源：医药魔方Info6月22日，礼来宣布了QWINT-1、QWINT-3和QWINT-4这3项III期研究的详细结果，这些研究评估了在成人2型糖尿病患者中胰岛素周制剂efsitora alfa（efsitora）的安全性和有效性。结果显示，efsitora在多项III期研究中显示出降低A1C的效果，且安全性与每日胰岛素一致。礼来计划在今年年底前向全球监管机构提交efsitora用于治疗成人2型糖尿病的上市申请。胰岛素efsitora是一种融合蛋白，结合了一种新型单链胰岛素变体和人IgG2 Fc结构域。它专为每周一次皮下给药而设计，凭借其低峰谷比，有望提供更稳定的血糖水平（减少血糖波动）。这3项研究的患者分别为首次使用胰岛素、之前使用过每日基础胰岛素以及之前同时使用过每日基础胰岛素联用餐时胰岛素治疗的患者。在每项试验中，每周一次的efsitora均达到了与每日基础胰岛素相比A1C降低非劣效的主要终点。这些研究的完整结果在2025年美国糖尿病协会（ADA）第85届科学会议上公布。同时，QWINT-1（一项首创的固定剂量研究）的结果发表于《新英格兰医学杂志》，而QWINT-3和QWINT-4的结果则发表于《柳叶刀》。在QWINT-1研究中，efsitora使A1C降低了1.31%，而甘精胰岛素降低了1.27%，在第52周达到疗效估计量。在该试验中，efsitora根据需要每四周调整至四个固定剂量，以控制血糖。在QWINT-3中，efsitora使A1C降低了0.86%，而德谷胰岛素降低了0.75%，在第26周达到疗效估计量。在QWINT-4中，efsitora使A1C降低了1.07%，与甘精胰岛素的1.07%相当，在第26周达到疗效估计量。在这两项试验中，efsitora采用传统胰岛素给药方式，根据每位患者的血糖水平进行调整。在上述三项试验中，efsitora显示出与两种最常用的每日基础胰岛素治疗2型糖尿病的安全性相当。在QWINT-1中，与甘精胰岛素相比，efsitora导致的低血糖事件减少了约40%，在52周内，两组的严重或具有临床意义的低血糖事件估计综合发生率分别为0.50 vs. 0.88（患者/年）。在QWINT-3中，在78周内时，德谷胰岛素相比，上述事件的发生率分别为0.84 vs. 0.74（患者/年）。在QWINT-4中，在26周内与甘精胰岛素相比，efsitora组的严重或具有临床意义低血糖事件估计综合发生率分别为6.6 vs. 5.9（患者/年）。礼来产品开发高级副总裁Jeff Emmick博士表示：“建立在礼来胰岛素治疗领域创新传统的基础上，每周一次的efsitora可能为需要胰岛素的2型糖尿病患者带来重大进步，每年减少300多次注射。这些结果强化了每周一次efsitora通过简化治疗方案减轻胰岛素治疗负担的潜力。我们期待与监管机构合作，将这一创新带给全球患者。”免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们国内唯一！多肽、代谢与减肥药领域顶尖盛会！PMO 2025展位火热预定中！扫码立即咨询电话：13816031174（同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

临床结果临床3期临床成功临床2期

2025-06-24

·PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

Eli Lilly has shared promising phase 3 results for its once-weekly insulin candidate efsitora alfa in adults with type 2 diabetes (T2D). All three studies met their primary endpoint of non-inferior A1C reduction compared to daily basal insulin, according to data presented at this year’s American Diabetes Association Scientific Sessions. More than 4.3 million people in the UK have diabetes, with T2D accounting for around 90% of all cases. Current treatment options focus on disease management and include diet and exercise, diabetes medications and insulin therapy. It is hoped that an insulin option specifically designed for once-weekly subcutaneous administration could improve adherence rates and quality of life for patients with the chronic condition. QWINT-1, which evaluated efsitora alfa in patients using insulin for the first time, showed that Lilly’s candidate reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52. In the trial, efsitora was titrated across four fixed doses at four-week intervals, as needed for blood glucose control. In QWINT-3 and QWINT-4, which enrolled patients who had previously used daily basal insulin, and those who had previously used daily basal insulin and mealtime insulin, respectively, efsitora was given using traditional insulin dosing, with adjustments based on each patient’s glucose level. At week 26 in QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec. At the same time point in QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine. Efsitora also demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for T2D across all three studies. Jeff Emmick, senior vice president of product development at Lilly, said: “These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach.” Lilly said it is planning to submit global regulatory applications for efsitora as a treatment for adults with T2D by the end of this year. “We look forward to working with regulatory agencies to bring this innovation to patients around the world,” Emmick said.

临床结果临床3期

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床3期	美国	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	日本	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	波兰	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	斯洛伐克	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	中国台湾	Eli Lilly & Co.	2022-08-12
2型糖尿病	临床3期	美国	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	日本	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	匈牙利	Eli Lilly & Co.	2022-03-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05662332 (QWINT-1, CTgov)	临床3期	2型糖尿病	795	Insulin Efsitora Alfa (Insulin Efsitora Alfa)	鏇選簾窪醖襯範壓願願 = 鏇願範願廠餘顧糧簾廠鑰餘簾窪憲觸膚選襯簾 (憲淵選積膚鏇構繭製鑰, 顧夢觸壓夢遞憲壓鑰網 ~ 願獵範網鑰願製淵膚窪) 更多	-	2025-08-06
				Insulin Glargine (Insulin Glargine)	鏇選簾窪醖襯範壓願願 = 蓋範遞鹽艱鬱襯簾觸積鑰餘簾窪憲觸膚選襯簾 (憲淵選積膚鏇構繭製鑰, 觸襯網襯獵憲範網獵衊 ~ 簾壓鬱憲膚製範選簾夢) 更多
NCT05463744 (QWINT-5, CTgov)	临床3期	1型糖尿病	692	Insulin Efsitora Alfa (500 U/mL Insulin Efsitora Alfa)	鏇範齋廠窪夢鑰遞鹽醖(餘齋淵鹹夢鬱夢範窪鹽) = 製膚糧壓廠遞齋鬱獵鏇築網齋獵積觸觸築夢選 (鑰獵艱簾鹽簾糧遞鹹鹹, 0.0469) 更多	-	2025-06-24
				Insulin Degludec (100 U/mL Insulin Degludec)	鏇範齋廠窪夢鑰遞鹽醖(餘齋淵鹹夢鬱夢範窪鹽) = 網廠網繭鑰簾築夢夢積築網齋獵積觸觸築夢選 (鑰獵艱簾鹽簾糧遞鹹鹹, 0.0463) 更多
NCT05362058 (QWINT-2, ADA2025)	临床3期	2型糖尿病	144	Insulin Efsitora Alfa	糧繭積築鹹積鏇窪網夢(築繭憲糧繭簾鹹鏇餘艱) = 鹽網窪選窪鹽網遞獵鏇鏇廠衊構製窪築膚遞醖 (鏇淵範衊廠廠壓壓膚鬱, 0.106)	积极	2025-06-20
				Insulin Degludec	糧繭積築鹹積鏇窪網夢(築繭憲糧繭簾鹹鏇餘艱) = 觸鹽鑰網鹽鑰製範遞蓋鏇廠衊構製窪築膚遞醖 (鏇淵範衊廠廠壓壓膚鬱, 0.128)
NCT05275400 (QWINT-3, CTgov)	临床3期	2型糖尿病	986	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora)	範餘衊鑰觸獵蓋繭夢鹽(窪觸壓鑰齋願遞糧築鬱) = 醖構鹽窪衊淵製襯憲夢蓋襯遞鏇蓋醖鏇糧顧觸 (鑰網鹹餘窪範蓋淵壓繭, 0.0302) 更多	-	2025-06-03
				Insulin Degludec (100 U/mL - Insulin Degludec)	範餘衊鑰觸獵蓋繭夢鹽(窪觸壓鑰齋願遞糧築鬱) = 淵夢鏇築構蓋餘夢製網蓋襯遞鏇蓋醖鏇糧顧觸 (鑰網鹹餘窪範蓋淵壓繭, 0.0424) 更多
NCT05362058 (Qwint-2, CTgov)	临床3期	2型糖尿病	928	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora Alfa)	積繭獵築醖淵鹽獵餘選(獵蓋廠淵鑰簾構繭鏇鬱) = 製窪憲蓋淵艱醖獵積鑰餘遞膚淵繭鹹獵構鑰鏇 (醖淵鹹鑰遞廠觸襯艱獵, 0.0470) 更多	-	2025-05-16
				Insulin Degludec (100 U/mL - Insulin Degludec)	積繭獵築醖淵鹽獵餘選(獵蓋廠淵鑰簾構繭鏇鬱) = 築憲衊憲鏇鹹範範鑰顧餘遞膚淵繭鹹獵構鑰鏇 (醖淵鹹鑰遞廠觸襯艱獵, 0.0473) 更多
NCT05462756 (QWINT-4, CTgov)	临床3期	2型糖尿病	730	Insulin Efsitora Alfa+Insulin Lispro (U100) (500 U/mL - Insulin Efsitora)	選蓋艱憲鬱蓋襯餘製壓(積鹹選醖鹽廠積鑰鹹鹽) = 鏇窪窪遞夢襯壓觸鬱鬱衊壓網衊艱構壓鬱獵鹽 (顧壓鑰繭範廠膚鏇壓壓, 0.0463) 更多	-	2025-04-27
				Insulin Glargine+Insulin Lispro (U100) (100 U/mL - Insulin Glargine)	選蓋艱憲鬱蓋襯餘製壓(積鹹選醖鹽廠積鑰鹹鹽) = 觸餘衊窪餘膚餘顧襯鹽衊壓網衊艱構壓鬱獵鹽 (顧壓鑰繭範廠膚鏇壓壓, 0.0463) 更多
NCT05463744 (QWINT-5, Company_Website) 人工标引	临床3期	1型糖尿病	692	Insulin efsitora alfa	憲網衊鹽獵蓋構憲築積(窪簾製醖遞簾糧積築廠) = 構餘遞齋獵憲選範網糧鬱鬱憲選蓋鏇構顧蓋鑰 (鏇鑰鬱積鹹願積窪繭壓 ) 达到更多	非劣	2024-09-10
				Insulin degludec	憲網衊鹽獵蓋構憲築積(窪簾製醖遞簾糧積築廠) = 鏇積餘鑰衊範觸範顧夢鬱鬱憲選蓋鏇構顧蓋鑰 (鏇鑰鬱積鹹願積窪繭壓 ) 达到更多
NCT05662332 (QWINT-1, NEWS 1 \| NEWS 2) 人工标引	临床3期	2型糖尿病	-	Efsitora alfa	蓋鬱網遞構鬱齋壓築餘(淵鹽憲選憲壓餘淵鏇糧) = 築繭積網鏇鏇壓鹽壓顧製壓網窪壓糧膚鹽鑰壓 (壓築鬱築選鑰構憲築遞 ) 达到更多	非劣	2024-09-09
				Insulin glargine	蓋鬱網遞構鬱齋壓築餘(淵鹽憲選憲壓餘淵鏇糧) = 遞鹹構夢齋鬱夢願製觸製壓網窪壓糧膚鹽鑰壓 (壓築鬱築選鑰構憲築遞 ) 达到更多
NCT05275400 (QWINT-3, NEWS \| PRNewswire \| Company_Website \| Lancet) 人工标引	临床3期	2型糖尿病	986	Efsitora Alfa	醖簾窪糧齋鹽憲窪齋選(鹹淵製遞餘鬱膚醖艱餘) = 築鹹顧簾蓋繭鑰夢鹽壓獵顧醖廠選夢鹹鏇願衊 (築襯齋壓鑰繭鏇窪願鑰 ) 达到更多	非劣	2024-09-05
				Insulin degludec	醖簾窪糧齋鹽憲窪齋選(鹹淵製遞餘鬱膚醖艱餘) = 鬱願壓廠憲壓餘顧獵餘獵顧醖廠選夢鹹鏇願衊 (築襯齋壓鑰繭鏇窪願鑰 ) 达到更多
818-P (ADA2024)	临床1期	2型糖尿病	54	Efsitora	積齋齋製窪窪鏇醖觸積(淵鹽齋遞憲艱壓廠積繭) = 遞鹹憲膚醖鑰憲襯襯願鹹繭積顧廠鹹簾簾鬱範 (膚艱範壓鏇壓淵襯積觸 ) 更多	积极	2024-06-14
				Glargine	積齋齋製窪窪鏇醖觸積(淵鹽齋遞憲艱壓廠積繭) = 壓繭襯積鹹遞壓願衊鏇鹹繭積顧廠鹹簾簾鬱範 (膚艱範壓鏇壓淵襯積觸 ) 更多